To Assess Use of Vancomycin Powder in Craniotomy on Wound Infection Rates
Primary Purpose
Wound Infection
Status
Unknown status
Phase
Phase 4
Locations
Qatar
Study Type
Interventional
Intervention
Vancomycin
Sponsored by
About this trial
This is an interventional treatment trial for Wound Infection
Eligibility Criteria
Inclusion Criteria:
- Any type of craniotomy whatever the cause.
- Age more than 18 Years
- Patient with no evidence of any source of infection
Exclusion Criteria:
- Any evidence of infection.
- Age less than 18 years
- Previous and multiple craniotomies
- Active infection
- Craniectomy
- wound laceration over the craniotomy site.
Sites / Locations
- Hamad General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
vancomycin group (intervention arm)
control group
Arm Description
We will use one vial of vancomycin that contains 1000 mg of the drug in powder form on the surgical site before closing the wound
no vancomycin powder will be used
Outcomes
Primary Outcome Measures
rate of wound infection
to assess the effectiveness of vancomycin in craniotomy on the surgical site infection rate as compared to controls.
Secondary Outcome Measures
asses the rate wound complication
to assess the complications of intrawound vancomycin like seroma , long term benefit and cost effectiveness of vancomycin use on hospital stay and patient recovery, and to look for any other infection at 3 months follow up.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04917627
Brief Title
To Assess Use of Vancomycin Powder in Craniotomy on Wound Infection Rates
Official Title
Randomized Controlled Trial Assessing Use of Vancomycin Powder in Craniotomy on Wound Infection Rates
Study Type
Interventional
2. Study Status
Record Verification Date
June 2021
Overall Recruitment Status
Unknown status
Study Start Date
May 1, 2021 (Actual)
Primary Completion Date
May 1, 2022 (Anticipated)
Study Completion Date
May 1, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hamad General Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Surgical site infection (SSI) after craniotomy is a major cause of morbidity and mortality besides its major health care cost. In each hospital, all measures are taken to decrease SSI. Despite current prophylactic measures, rates of SSIs have been reported in up to 5% of patients post craniotomy. Intrawound vancomycin powder has been studied extensively in spinal fusion surgeries and been found to reduce rates of surgical site infections (SSIs) significantly. Despite its success in spinal surgeries, topical vancomycin has not been extensively studied with respect to cranial neurosurgery.
The use of adjuvant vancomycin powder was associated with a significant reduction in the incidence of postoperative infection as well as infection-related medical costs. These findings suggest that the use of adjuvant vancomycin powder in high-risk patients undergoing spinal fusion is a cost-saving option for preventing postoperative infections, as it can lead to cost-savings of $438,165 per 100 spinal fusions performed.
The investigators believe that Topical vancomycin is a safe, effective, and cost-saving measure to prevent SSIs following craniotomy.
Detailed Description
its Prospective Randomized clinical trial. The investigator will do block randomization that is done by a biostatistician through SAS software . Patients will be divided in this Trial into two groups, first group (intervention arm) they will receive the drug (vancomycin). The second group (control arm) they will not receive the drug, otherwise both groups they will receive identical measure to decrease the postoperative SSI.
The investigator will use one vial of vancomycin that contains 1000 mg of the drug in the powder form.
The primary outcome variable will be SSI rate factored by cohort. Secondary outcome will be cost savings from vancomycin usage estimated from hospital costs associated with SSI in craniotomy patients, morbidity and mortality.
SSI found to be around 0.49% when vancomycin was used, while SSI in standard care found to be 5%, to get power of study 80% and level of significance 5%. Sample size will be 250 in each group using sample size calculator.
The statistical formula used in computation of required and adequate sample size in view of primary outcome i.e., SSI rate between the two groups:
The sample size was computed using the following statistical formula and sample size determination equation:
n = (Zα/2+Zβ)2 * (p1(1-p1)+p2(1-p2)) / (p1-p2)2
Where Zα/2 is the critical value of the Normal distribution at α/2 (e.g. for a confidence level of 95%, α is 0.05 and the critical value is 1.96), Zβ is the critical value of the Normal distribution at β (e.g. for a power of 80%, β is 0.2 and the critical value is 0.84) and p1 and p2 are the expected sample proportions of the two groups (SSI rate between the two groups i.e., vancomycin and control groups).
Before the study starts the investigator will do automated coded file with each code randomized to either arm (intervention arm and regular arm), then patient will be assigned to subsequent arm according to the code. CONSORT guidelines will be followed when reporting the results of the trail.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Wound Infection
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
500 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
vancomycin group (intervention arm)
Arm Type
Active Comparator
Arm Description
We will use one vial of vancomycin that contains 1000 mg of the drug in powder form on the surgical site before closing the wound
Arm Title
control group
Arm Type
No Intervention
Arm Description
no vancomycin powder will be used
Intervention Type
Drug
Intervention Name(s)
Vancomycin
Other Intervention Name(s)
vancomax 1000mg powder form, KULLANMA TALİMATI
Intervention Description
one vial of vancomycin (1000 mg ) powder form.
Primary Outcome Measure Information:
Title
rate of wound infection
Description
to assess the effectiveness of vancomycin in craniotomy on the surgical site infection rate as compared to controls.
Time Frame
24 months
Secondary Outcome Measure Information:
Title
asses the rate wound complication
Description
to assess the complications of intrawound vancomycin like seroma , long term benefit and cost effectiveness of vancomycin use on hospital stay and patient recovery, and to look for any other infection at 3 months follow up.
Time Frame
24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Any type of craniotomy whatever the cause.
Age more than 18 Years
Patient with no evidence of any source of infection
Exclusion Criteria:
Any evidence of infection.
Age less than 18 years
Previous and multiple craniotomies
Active infection
Craniectomy
wound laceration over the craniotomy site.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
sirajeddin belkhair
Phone
+97466349091
Email
sbelkhair@hamad.qa
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
sirajeddin belkhair
Organizational Affiliation
Hamad General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hamad General Hospital
City
Doha
Country
Qatar
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
sirajeddin belkhair
Phone
+97466349091
Email
sbelkhair@hamad.qa
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
To Assess Use of Vancomycin Powder in Craniotomy on Wound Infection Rates
We'll reach out to this number within 24 hrs